Abstract:Objectives: In tumor immune microenvironment, the functions of tumor-associated macrophages (TAMs), including phagocytosis and immunomodulatory, have attracted increasing attention recently. With the discovery of CD47-signal regulatory protein-alpha (SIRP alpha) as "don't eat me" signaling pathway, the role of novel subpopulation of TAMs expressing SIRP alpha has not been fully elucidated in a wide spectrum of solid tumors including bladder cancer. In this study, we investigated the prognostic and predictive implication of SIRP alpha(+) TAMs regarding clinical outcomes and adjuvant chemotherapeutic benefit in muscle-invasive bladder cancer (MIBC), and preliminarily characterized the phenotypic features of SIRP alpha(+) TAMs and its relationship with immune contexture. Materials and methods: A total of 141 histochemical MIBC samples from Zhongshan Hospital (ZS), 45 fresh tissue samples, and 391 MIBC patients from TCGA database were enrolled in this study. SIRP alpha(+) TAMs was evaluated by immunohistochemical staining of CD68 and SIRP alpha, and flow cytometry fluorescence staining. Results: Our results illustrated that SIRP alpha(+) TAMs were enriched in MIBC specimens. Patients with high SIRP alpha(+) TAMs infiltration suffered significant poor overall survival and recurrence-free survival (P = 0.0030 and P = 0.0282). SIRP alpha(+) TAMs infiltration was an independent prognosticator in multivariate Cox model. Moreover, adjuvant chemotherapy (ACT) application showed significantly survival benefit in patients with low SIRP alpha(+) TAMs infiltration (P = 0.0135). SIRP alpha(+) TAMs with suppressive phenotype exhibited a positive correlation with immune tolerance and dysfunctional CD8(+) T cells in MIBC. Conclusions: SIRP alpha(+) TAMs infiltration indicated poor prognosis and ACT resistance in MIBC. Immunosuppressive SIRP alpha(+) TAMs is closely related to immune evasion with exhausted T cells states, suggesting the prospect of SIRP alpha(+) TAMs as a potential therapeutic target in MIBC. (C) 2021 Elsevier Inc. All rights reserved.

Tumor-associated Macrophages Expressing Galectin-9 Identify Immunoevasive Subtype Muscle-Invasive Bladder Cancer with Poor Prognosis but Favorable Adjuvant Chemotherapeutic Response

Immunosuppressive Tumor-Associated Macrophages Expressing Interlukin-10 Conferred Poor Prognosis and Therapeutic Vulnerability in Patients with Muscle-Invasive Bladder Cancer.

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer.

Stromal LAG-3+cells Infiltration Defines Poor Prognosis Subtype Muscle-Invasive Bladder Cancer with Immunoevasive Contexture

Poor clinical outcomes and immunoevasive contexture in SIRP<SUP>+</SUP> tumor-associated macrophages enriched muscle-invasive bladder cancer patients

Siglec9 + Tumor-Associated Macrophages Predict Prognosis and Therapeutic Vulnerability in Patients with Colon Cancer.

Intratumoral TIGIT + CD8 + T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer

B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients

Tumor Stroma-Infiltrating Mast Cells Predict Prognosis and Adjuvant Chemotherapeutic Benefits in Patients with Muscle Invasive Bladder Cancer.

Single-cell Sequencing Data Reveals Aggressive CD68-type Macrophages and Prognostic Models in Bladder Cancer.

Identification and Validation of an Excellent Prognosis Subtype of Muscle-Invasive Bladder Cancer Patients with Intratumoral CXCR5+ CD8+ T Cell Abundance.

Poor Clinical Outcomes and Immunoevasive Contexture in Interleukin‐9 Abundant Muscle‐invasive Bladder Cancer

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68/PD-1 Complex Interactions

Intratumoral IL22-producing Cells Define Immunoevasive Subtype Muscle-Invasive Bladder Cancer with Poor Prognosis and Superior Nivolumab Responses

High infiltration of mast cells associates with improved response to adjuvant chemotherapy in gallbladder cancer.

CD19(+) Tumor-Infiltrating B-cells Prime CD4(+) T-cell Immunity and Predict Platinum-Based Chemotherapy Efficacy in Muscle-Invasive Bladder Cancer

Tumor-infiltrating IL-17A+ Cells Determine Favorable Prognosis and Adjuvant Chemotherapeutic Response in Muscle-Invasive Bladder Cancer

Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies